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Abstract 26 
Limited data exist regarding prognostic factors and optimal antimicrobial treatment of 27 
infections from extensively drug-resistant (XDR) Acinetobacter baumannii (AB). This 28 
retrospective cohort study included 93 adult patients who developed ventilator-associated 29 
pneumonia (VAP) due to XDR-AB in the intensive-care unit of the University Hospital of 30 
Heraklion, Greece, from October 2012 to April 2015. XDR-AB isolates were mainly 31 
susceptible to colistin (93.5%) and tigecycline (25.8%), whereas 6 (6.5%) strains were 32 
pandrug-resistant. Prior to infection, patients had long durations of mechanical ventilation 33 
and hospital stay and multiple exposures to antibiotics. Median Charlson comorbidity and 34 
APACHE II scores were 2 and 17, respectively. Mortality at 28 days of infection onset was 35 
high (34.4%), despite the high rates of active-in-vitro empirical (81.7%) and definitive 36 
(90.3%) treatment. Active colistin-based combination therapy (n=55) and monotherapy 37 
(n=29) groups had similar 28-day mortality (27.6% vs 30.9%, respectively) and Kaplan-38 
Meier survival estimates over time. In multivariable Cox regression, advanced age (adjusted 39 
hazard ratio [aHR] 1.05 per year increase; 95% confidence interval [CI] 1.02 – 1.09), rapidly 40 
fatal underlying disease (aHR 2.64; 95% CI 0.98–9.17) and APACHE II score (aHR 1.06 per 41 
unit increase; 95% CI 0.99-1.14) were identified as independent predictors of 28-day 42 
mortality, but no difference in mortality hazards between the active colistin-based 43 
combination therapy and monotherapy groups was produced (aHR 0.88; 95% CI 0.35–2.38). 44 
These results support the use of colistin as a first-line agent against VAP in settings where 45 
XDR-AB is endemic, but oppose the introduction of colistin-based combination therapy as 46 
standard treatment. 47 
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1. ǿntroduction  51 
Ventilator-associated pneumonia (VAP) is a common lethal infection in critical care settings 52 
which is also associated with increased morbidity and health care costs [1].  Acinetobacter 53 
baumannii (AB), a pathogen with an alarming ability to rapidly develop antimicrobial 54 
resistance, is a major cause of VAP worldwide [1,2]. The emergence of extensively-drug 55 
resistant (XDR) strains that are resistant to all but one or two antibiotic classes and often 56 
cause hospital outbreaks has become a serious public health threat [2–6].  However, clinical 57 
studies in affected patients are scarce and factors predictive of poor outcome have rarely been 58 
investigated [7]. Importantly, limited in vivo data exist on the efficiency of the few 59 
therapeutic options available to treat infections from XDR Gram-negative bacteria. Currently, 60 
there are suggestions in the literature that combination therapy should be used, which may 61 
even include antibiotics to which the causative pathogen demonstrates in vitro resistance  62 
[5,8];  but these have been severely criticized [9].  63 
 The purpose of this study is to describe the clinical and therapeutic profile of XDR-64 
AB VAP in a cohort of critically ill patients and assess prognostic factors of 28-mortality, 65 
with a focus on elucidating the effect of active definitive treatment regimens. 66 
 67 
2. Materials and methods 68 
2.1 Setting and study design 69 
A retrospective cohort study was conducted in the adult intensive care unit (ICU) of the 70 
University Hospital of Heraklion, from October 2012 to April 2015. This is a 750-bed 71 
tertiary-care institution that receives approximately 55,000 admissions per year and serves as 72 
a referral hospital for the island of Crete in Greece.  The ICU has 12 beds and covers for all 73 
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medical and surgical cases.  The study was approved by the hospital's Ethics Committee and 74 
is reported according to the STROBE recommendations [10]. 75 
The study cohort included all adult patients who were mechanically ventilated for 76 
more than 48 hours and developed VAP because of XDR-AB. Patients were eligible for 77 
inclusion if the infection developed during the ICU stay or were admitted to the ICU for this 78 
infection. Only the first episode of XDR-AB VAP was recorded for each patient. Patients 79 
with polymicrobial VAP and patients with other previous or concurrent infections were 80 
included in the study. Eligible patients were identified by review of clinical culture results as 81 
part of the hospital’s surveillance programme to identify multidrug-resistant isolates.  82 
 83 
2.2 Data collection and definitions 84 
VAP was defined as pneumonia that occurred in a patient at least 48 hours following 85 
mechanical ventilation. Pneumonia was defined according to the Centers for Disease Control 86 
and Prevention criteria [11]. Patients with no clinical symptoms or radiological evidence of 87 
an infiltrate were considered to have colonization and were excluded from the study. Onset of 88 
VAP was defined as the date of collection of the first clinical culture that yielded the study 89 
organism. The diagnosis of VAP was confirmed by positive quantitative microbial cultures of 90 
aspirate: (1) non-protected bronchoscopic specimen cultures >106 colony forming units 91 
(cfu)/mL, (2) specimen cultures obtained by transbronchial aspirate >105 cfu/mL, or (3) 92 
protected bronchoscopic lavage cultures >104 cfu/mL.  93 
XDR-AB was resistant to all except for two or less classes of antibiotics [4]. Species 94 
identification and antibiotic susceptibility testing were performed by the Vitek 2 system 95 
(bioMérieux SA, Marcy L’Etoile, France) in accordance with the Clinical and Laboratory 96 
Standards Institute standards for all antibiotics except tigecycline [12]. Susceptibility to 97 
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tigecycline was performed by the Etest (AB Biodisk, Solna, Sweden). According to the 98 
susceptibility breakpoints of Enterobacteriaceae used by the U.S. Food and Drug 99 
$GPLQLVWUDWLRQ DQ $% RUJDQLVP ZLWK DQ 0,& ȝg/mL to tigecycline was considered 100 
susceptible [13]. 101 
Clinical, biological and treatment data were obtained retrospectively from the 102 
patients’ medical charts and electronic records. Co-morbid conditions were recorded in 103 
accordance with the Charlson weighted co-morbidity index [14]. The underlying illnesses at 104 
the time of admission in the ICU were classified as rapidly fatal, ultimately fatal, and nonfatal 105 
according to the McCabe and Jackson classification [15]. Acute Physiology and Chronic 106 
Health Evaluation (APACHE) II scores were measured at the time of ICU admission and at 107 
VAP onset [16]. 108 
Data on antimicrobial therapy, as selected at the discretion of the attending 109 
physicians, were recorded. Treatment given before obtaining susceptibility results was 110 
defined as “empirical”. Therapy given after the susceptibility data became available was 111 
defined as “definitive”. An “active” drug was an antibiotic to which XDR-AB was in vitro 112 
susceptible. Definitive treatment regimens were classified as monotherapy (treatment with 113 
only one in vitro active agent) or combination therapy (treatment with two or more in vitro 114 
active agents). According to our institutional guidelines for the administration of last line 115 
antibiotics and in the absence of impaired renal function, antibiotic regimens were 116 
standardized and administered as follows: colistin as a 9 million IU loading dose followed 117 
after 24 hours by 3 million IU every 8 hours; tigecycline 100 mg every 12 hours; high dose 118 
prolonged infusion of carbapenems, ie. meropenem 2g over 4 hours every 8 hours or 119 
imipenem 1g over 3 hours every 8 hours. Dosages were adjusted to renal function as 120 
indicated [17]. Inhaled antibiotics were not regularly administered. The duration of all 121 
definitive treatment regimens ranged from 7 to 10 days.  122 
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2.3 Statistical analysis 124 
Data were processed and analysed using the SPSS 22 software package (IBM, New York, 125 
USA). The main outcome measured was the all-cause mortality within 28 days after the onset 126 
of VAP. Patients discharged before day 28 were considered survivors. Mortality was 127 
analysed both as a binary outcome (yes/no) and as survival time data with patients discharged 128 
before day 28 or hospitalized and alive at day 28 considered censored observations. Survivors 129 
and nonsurvivors were compared to identify independent prognostic factors among a set of 130 
variables which were chosen a priori based upon clinical judgment and previous studies in 131 
different settings. Emphasis was given on elucidating the effect of active definitive treatment 132 
(i.e. monotherapy versus combination therapy). 133 
Bivariate associations between categorical variables were assessed using the Ȥ2 test or 134 
Fisher’s exact test, whereas the Mann-Whitney U test was used for continuous predictor 135 
variables. In the survival analysis, Kaplan-Meier estimates of the probability of survival were 136 
obtained and survival curves were compared between groups using the log rank test. A 137 
multivariable Cox proportional hazards model was used to identify prognostic factors 138 
independently associated with 28-day mortality. To avoid excluding potentially useful 139 
prognostic factors, the purposeful approach for selecting variables was used [18]. Variables 140 
that were identified from univariate analysis as statistically significant at a conservative alpha 141 
level of 0.25 were initially assessed using backward stepwise selection (exclusion/inclusion: 142 
P3! UHVSHFWLYHO\ ZLWK WKH OLNHOLKRRG-ratio test.  Variables that did not retain 143 
statistical significance at the usual significance level of 0.05 were tested for confounding by 144 
adding them one at a time to the model and examining their impact on the effect estimate for 145 
the treatment variable. Those causing substantial confounding (change in the hazard ratio 146 
greater than 10%) were retained in the final model. Empirical and definitive treatment, being 147 
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predictor variables of primary clinical interest, were forced into the model. Confidence 148 
intervals were calculated by the profile likelihood method. Collinearity was assessed by 149 
examining pairwise correlations and variance inflation factors. Tests of time-covariate 150 
interactions were used to verify the PH assumption and bootstrap was employed to assess the 151 
validity of standard errors in the final cox regression model. 152 
Patients who died within 48h after the onset of infection and those who received 153 
definitive treatment with no active drug were excluded from the analysis of prognostic 154 
factors. Patients with polymicrobial infection were included in the analysis only if they had 155 
received antibiotics active in vitro against the other co-infecting organism(s). 156 
 157 
3. Results 158 
Of the 1333 adult patients who were admitted to the ICU during the 31-month study period, 159 
124 (9.3%) patients had XDR-ǹǺ isolated in the aspirate. A total of 93 (75%) of those 160 
patients fulfilled the diagnostic criteria for VAP and were included in the study. The hospital-161 
wide incidence rate of XDR-AB VAP was 2.6/10,000 patient-days and 90.3/10,000 ICU-162 
days.  163 
 164 
3.1 Baseline characteristics on ICU admission  165 
The mean age of the patients was 59.7 ± 18.3 years (median, 62 years; range, 17 to 92 years) 166 
and 71 (76.3%) patients were male. Admission diagnoses to the ICU were acute respiratory 167 
failure in 29 patients (31.2%), multiple trauma (21 patients, 22.6%), septic shock - multiorgan 168 
failure (14 patients; 15.1%), cerebral haemorrhage (11 patients; 11.8%) postoperative 169 
observation (7 patients; 7.5%), acute neurological complications (6 patients; 6.5%) and post-170 
resuscitation syndrome (5 patients; 5.4%). The most frequent underlying diseases were 171 
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diabetes mellitus in 24 (25.8%) patients, malignancy in 19 (20.4%) patients, and chronic 172 
pulmonary disease in 14 (15.1%) patients.  The mean Charlson comorbidity index was 2.7 ± 173 
2.7 (median, 2; interquartile range, 0-5), mean APACHE II score was 19.0 ± 7.5 (median, 17; 174 
interquartile range, 14-23), and 84.9% of the patients were classified as having a rapidly fatal 175 
or ultimately fatal underlying disease. 176 
 177 
3.2 Clinical characteristics of infections and empirical treatment 178 
Prior to the onset of XDR-AB VAP, the mean duration of mechanical ventilation was 13.6 ± 179 
14.2 days (median, 10; interquartile range 6-15.5) and the mean length of stay in the ICU was 180 
13.5 ± 14.3 days (median, 11; interquartile range 5.5-15.5). Eighty-four patients (90.3%) had 181 
a history of antibiotic use in the 30 days preceding the onset of VAP, which most frequently 182 
included b-lactam/b-lactamase inhibitor combinations (45 patients), carbapenems (43 183 
patients), glycopeptides (25 patients), colistin (23 patients) and cephalosporins (22 patients). 184 
During the XDR-AB VAP, ten patients (10.8%) experienced septic shock, 14 (15.1%) 185 
developed severe sepsis and 8 (8.6%) developed multi-organ failure. 186 
Susceptibility testing showed that all XDR-AB strains were non-susceptible to 187 
carbapenems and aminoglycosides, 69 strains (74.2%) were non-susceptible to tigecycline, 188 
and 6 strains (6.5%) were non-susceptible to colistin; all of the latter were pandrug-resistant, 189 
i.e. resistant to all antibiotics tested. 190 
For empirical treatment of XDR-AB VAP, 76 (81.7%) patients received at least one 191 
active drug, while 17 (18.3%) patients received no active empirical drug. Empirical regimens 192 
were largely colistin-based (77 patients; 83.7%), including colistin alone (22 patients; 193 
23.7%), or colistin combined with carbapenem (29 patients; 31.2%), with tigecycline (22 194 
patients; 23.7%), or with carbapenem and tigecycline (4 patients; 4.3%). 195 
 9 
 196 
3.3 Definitive antimicrobial treatment and treatment outcomes 197 
Definitive antimicrobial treatment was administered 48 to 72 hours after the onset of VAP. 198 
Five patients (5.4%) were infected with pandrug-resistant AB and received therapy with no 199 
active drug. Four patients (4.3%) died within 48h after the onset of VAP, before the 200 
susceptibility results were available, including one patient infected with pandrug-resistant 201 
AB. In total, 84 (90.3%) subjects received at least one XDR-AB-active drug: 29 patients 202 
(34.5%) received combination therapy comprising two active antibiotics which were colistin 203 
plus tigecycline. The remaining 55 patients (65.6%) received monotherapy with active 204 
colistin. All patients with polymicrobial VAP received at least one antibiotic which was 205 
active against the other co-infecting organism(s). 206 
The monotherapy and combination therapy groups were comparable in terms of ICU 207 
admission diagnosis, comorbidity index, severity of underlying disease, APACHE II score, 208 
length of stay before infection, and duration of mechanical ventilation before infection (Table 209 
1). However, younger patients and those infected by a strain susceptible to tigecycline were 210 
more likely to have received combination therapy. There were 32 deaths (34.4%) within 28 211 
days of the onset of XDR-AB VAP. Combination therapy and monotherapy groups had 212 
similar 28-day mortality rates (27.6% vs 30.9%, respectively; p=0.751) and Kaplan-Meier 213 
survival estimates over time (p=0.582), as seen in Fig. 1. There was no significant variation 214 
in 28-day mortality rates (Table 2) or survival times for the different regimens used for 215 
definitive treatment (Fig. 2). 216 
 217 
3.4 Prognostic factors of 28-day mortality  218 
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The effects of patient-, infection-, and treatment-related factors on 28-day mortality were 219 
assessed in a univariate Cox regression analysis (Table 3). Adverse outcome appeared to be 220 
more likely among females and patients with advanced age, higher Charlson comorbidity 221 
index, higher APACHE II score at onset of infection, and infection complications. Empirical 222 
treatment with at least one active antibiotic and use of combination therapy as opposed to 223 
monotherapy for definitive treatment did not appear to have any apparent association with 224 
poor outcome. In multivariable analysis, advanced age (adjusted HR = 1.05 per year increase, 225 
95%CI 1.02 – 1.09; p=0.001) and rapidly fatal disease (adjusted HR = 2.64. 95%CI 0.98 – 226 
9.17; p=0.054) were identified as independent predictors of adverse outcome, while length of 227 
hospital stay before infection onset was independently predictive of survival (adjusted HR = 228 
0.96 per day increase, 95%CI 0.92 – 1.00; p=0.035). Apache II score at the onset of infection 229 
was retained in the model as an important confounder. Neither the empirical nor the 230 
definitive treatment variables showed a significant association with 28-day mortality. 231 
 232 
4. Discussion 233 
In line with previous research [19–21], the  risk profile of patients who developed XDR-AB 234 
VAP in this study comprised of high disease severity, long hospital and ICU stay, long 235 
duration of mechanical ventilation, and prior exposure to several antibiotics. Reported 236 
mortality rates have been high, ranging between 38% and 46% despite appropriate treatment 237 
[7,22–25]. Similarly in this study, mortality reached 34% at 28 days following the onset of 238 
VAP despite the high rates of appropriate empirical and definitive treatment. In vitro inactive 239 
therapy presented even higher mortality: four of the six patients (67%) in this study who were 240 
infected with a pandrug resistant strain died, while in another study all patients with 241 
pneumonia due to XDR-AB who received a non-active antibiotic died within 28-days of 242 
infection onset [7]. The median APACHE II score of our patients at the time of infection 243 
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corresponds to an expected mortality rate of 12-24% [16]. Therefore the true attributable 244 
mortality of XDR-AB infections remains high, even when empirical and definitive treatment 245 
regimens are in vitro active. 246 
Colistin is widely used for the treatment of multidrug-resistant AB VAP [26] and is a 247 
recommended treatment option for pneumonia caused by multidrug-resistant AB [27]. XDR-248 
AB isolates remain largely susceptible to colistin in most settings [25], but excessive or 249 
inadequate use of colistin may be associated with the emergence of colistin-resistant strains 250 
[28]. On the other hand, high resistance rates are increasingly reported for other last-line 251 
antibiotics, such as tigecycline, not only in AB, but also in Enterobacteriaceae [28,29]. In our 252 
study, a notable percentage of patients had already received colistin in the month prior to 253 
VAP but only a small, though alarming, proportion of XDR-AB isolates (6.5%) exhibited 254 
resistance to colistin. In contrast, three quarters of XDR-AB isolates were non-susceptible to 255 
tigecycline and more than a third exhibited an MIC>8 ȝg/mL. Similarly high rates of non-256 
susceptibility to tigecycline have been previously reported in other studies of XDR-AB 257 
infections [30,31], while the development of resistance during treatment has also been 258 
documented [30]. Although few, new antibiotics that are active against gram-negative 259 
bacteria have been recently introduced into clinical practice, but clinical experience with 260 
infections from XDR pathogens is still limited [28]. 261 
The present study supports the use of intravenous colistin as an effective treatment of 262 
XDR-AB VAP, but our analysis showed that colistin combinations (with carbapenems and/or 263 
tigecycline) did not differ from colistin monotherapy in terms of mortality risk. Studies 264 
comparing the effectiveness of colistin combinations to colistin monotherapy in XDR-AB 265 
infections are scarce and conflicting. In a multicenter randomized controlled trial comparing 266 
colistin-rifampicin combinations to colistin monotherapy in XDR-AB infections (the majority 267 
of which were VAP), no difference was found in 30-day mortality, infection-related deaths, 268 
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or length of stay between the two treatment arms [24]. On the other hand, an observational 269 
multicentre study of XDR-AB bloodstream infections suggested that colistin combinations 270 
had significantly lower in-hospital mortality and higher microbiological eradication rates than 271 
colistin monotherapy [22]. Even more perplexing is the fact that other studies report 272 
conflicting results regarding the impact of different colistin combinations on patient survival. 273 
In one study, combinations of colistin with sulbactam, tigecycline or high-dose carbapenems 274 
had comparable 28-day survival rates which were significantly higher than those in the 275 
patient group that received non-active antibiotics [7]. Another study involving different types 276 
of infection due to XDR-AB (most of which were VAP) in solid organ transplant patients, 277 
reported that colistin-carbapenem combinations had significantly higher 28-day survival rate 278 
compared to other colistin combinations and other antibiotics [23]. Discrepancies between 279 
different studies may have resulted from heterogeneity in microbiological properties, 280 
infection types and antibiotic dosing schemes [5,23], but may also have arisen because of 281 
small sample sizes and a high potential for confounding and selection bias [9].  282 
Important implications from promoting combination therapy as a standard of care 283 
should also be emphasized. We have previously demonstrated the role of treatment and 284 
duration of treatment with combinations of fluoroquinolones and carbapenems (used 285 
coincidently or sequentially) in increasing the risk of subsequent infection with carbapenem-286 
resistant Klebsiella pneumoniae [32]. Unnecessary use of combination therapy may also 287 
result in  increased healthcare costs, selection pressure in hospitals where multidrug-resistant 288 
or XDR pathogens are already established, persistence of colonization, and increased risk of 289 
side effects or other adverse events such as Clostridium difficile infection [9,24].  290 
There are limitations and strengths in this study that should be acknowledged. First of 291 
all, the fact that this was a single-centre study may limit the generalizability of our results. 292 
Secondly, despite the fact that the electronic records in our ICU were complete and missing 293 
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values were not an issue, the retrospective nature of the study did not allow us to safely 294 
document antibiotic toxicity. Another issue is the subjectivity in the diagnosis of VAP: the 295 
nearly complete randomness of the level of agreement between observers has been previously 296 
demonstrated [33], while in another study, interobserver agreement was low for diagnosis of 297 
VAP compared to other infection types in the ICU [34]. Requiring a combination of clinical, 298 
microbiological and radiological parameters to confirm diagnosis increases the likelihood of 299 
variability, but confidence in the diagnosis of VAP is higher when specific clinical signs are 300 
present [34,35]. In our ICU, in an effort to limit variability in the diagnostic procedure, all 301 
infections are discussed between clinical staff and infectious diseases physicians.  302 
On the other hand, this study is one of the largest series of XDR-AB infections 303 
reported to date. The fact that we focused exclusively on XDR-AB VAP is a strong point in 304 
this study, as AB is among the most frequent causes of VAP worldwide. Further strengths in 305 
this study include the high percentage of active empirical treatment which limits the potential 306 
for a confounding effect on definitive therapy, and the use of optimal intravenous antibiotic 307 
dosing. Indeed, our patients received high dose and prolonged infusion of carbapenems; a 308 
loading dose of colistin; and high daily dose of tigecycline. Compared to conventional doses, 309 
these dosing schemes have been confirmed to be more efficacious in achieving the desired 310 
pharmacokinetic targets and result in higher rates of clinical response [28,29]. Moreover the 311 
main treatment groups compared in this study had similar baseline characteristics and were 312 
well balanced in important confounders, including disease severity and comorbidity indices 313 
upon admission in the ICU, length of stay and duration of mechanical ventilation before the 314 
onset of infection and prognosis at the onset of the infection as measured by the APACHE II 315 
score. 316 
 317 
5. Conclusion  318 
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The risk profile for XDR-AB VAP is characterized by high disease severity and comorbidity 319 
indexes, long hospital and ICU stay, long duration of mechanical ventilation and prior 320 
exposure to several antibiotics. Mortality following XDR-AB VAP remains high even when 321 
empirical and definitive treatment regimens are active in vitro. Intravenous colistin is an 322 
effective first-line antimicrobial against VAP in settings where XDR-AB is endemic. 323 
However, colistin-based combination therapy does not appear to offer improved survival 324 
compared to colistin monotherapy, opposing the introduction of combination therapy as 325 
standard treatment against XDR-AB VAP. 326 
 327 
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Table 1  454 
Characteristics of patients with extensively drug-resistant A. baumannii ventilator-associated pneumonia 455 
according to definitive active treatment regimen. 456 
Variable 
Monotherapy 
(n=55)d,e 
Combination 
therapy (n=29)d,f p-value 
Age (years), median (IQR) 66.0 (55.0 – 77.0) 57.0  (38.0 – 68.0) 0.018 
Female sex, no. (%) 14  (25.5) 5  (17.2) 0.392 
ICU admission diagnosis, no. (%)   0.518 
Septic shock - Multiorgan failure 8 (14.5) 3 (10.3)  
Acute respiratory failure 20 (36.4) 7 (24.1)  
Acute trauma 11 (20.0) 9 (31.0)  
Neurosurgery 11 (20.0) 5 (17.2)  
Other 5 (9.1) 5 (17.2)  
Charlson comorbidity index, median (IQR) 3.0 (0.0- 5.0) 1.0 (0.0 – 4.0) 0.159 
Rapidly fatal underlying disease, no. (%)a 36 (65.5) 24 (82.8) 0.095 
Length of hospital stay (days), median (IQR)b 14.0 (8.0 – 25.0) 13.0 (9.0 – 18.0) 0.696 
Length of ICU stay (days), median (IQR)b  11.0 (6.0 – 16.0) 12.0 (7.0 – 14.0) 0.578 
Duration of mechanical ventilation (days), median 
(IQR)b 
11.0 (6.0 – 15.0) 10.0 (7.0 – 16.0) 0.966 
APACHE II score, median (IQR)c 20.0 (12.0 – 22.0) 19.0 (15.0 – 21.0) 0.607 
Polymicrobial infection, no. (%) 26 (47.3) 16 (55.2) 0.491 
Secondary bacteraemia, no. (%) 12 (21.8) 3 (10.3) 0.192 
Concurrent infection, no. (%) 5 (9.3) 3 (10.3) 0.852 
In vitro susceptibility to antibiotics, no. (%)    
Imipenem-susceptible isolate 55 (100) 29 (100)  
Tigecycline-susceptible isolate 10 (18.2) 12 (41.4) 0.024 
Colistin-susceptible isolate 55 (100) 29 (100)  
 457 
IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation.  458 
a. Measured at time of admission in the ICU according to the McCabe-Jackson classification. 459 
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b. Measured before the onset of infection. 460 
c. Measured at the onset of infection. 461 
d. Excluding patients infected with a pandrug-resistant strain and those who died within 48 h of infection 462 
onset. 463 
e. Treatment with one in vitro active agent. 464 
f. Treatment with two or more in vitro active agents. 465 
 466 
 467 
 21 
Table 2  468 
All cause 28-day mortality of patients with extensively drug-resistant A. baumannii ventilator-associated 469 
pneumonia according to definitive treatment regimen.  470 
Antibiotic regimen 
No. of patientsa Mortality 
% Total Survived Died 
Active combination therapy     
Colistin + tigecycline 29 21 8 27.6 
Active monotherapy 55 38 17 30.9 
Colistin  15 8 30.9 
Colistin + carbapenem  15 5 34.8 
Colistin + tigecycline  5 3 25.0 
Colistin + tigecycline + carbapenem  3 1 37.5 
No active agent 6b 2 4 66.7 
a. Three patients died within 48 h after infection onset before antibiotic susceptibility results were 471 
available and were excluded from analysis. 472 
b. All six patients were infected with panresistant Acinetobacter baumannii. 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
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Table 3  483 
Analysis of factors associated with all-cause 28-day mortality in 84 patients with extensively drug-resistant A. baumannii ventilator-associated pneumonia. 484 
Variable Survived (n=59)e Died (n=25)e Unadjusted effectf Adjusted effectg 
Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value 
Age (years), median (IQR) 57.0 (41.0 – 72.0) 74.0 (68.0 – 78.0) 1.05 (1.02 - 1.08) <0.001 1.05 (1.02 – 1.09)h 0.001 
Female sex, no. (%) 10 (16.9) 12 (36.0) 2.75 (1.21 - 6.26) 0.023   
ICU admission diagnosis, no. (%)    0.338   
Septic shock - Multiorgan failure 8 (13.6) 3 (12.0) 1.57 (0.26 – 9.40)    
Acute respiratory failure 17 (28.8) 10 (40.0) 2.28 (0.50 – 10.40)    
Acute trauma 17 (28.8) 3 (12.0) 0.84 (0.14 – 5.04)    
Neurosurgery 9 (15.3) 7 (28.0) 2.64 (0.55 – 12.69)    
Other 8 (13.6) 2 (8.0) Ref.    
Charlson comorbidity index, median (IQR) 16.0 (13.0 – 20.0) 21.0 (16.0 – 28.0) 1.25 (1.08 - 1.44) 0.002   
Rapidly fatal underlying disease, no. (%)a 39 (66.1) 21 (84.0) 2.19 (0.75 – 6.39) 0.117 2.64 (0.98 – 9.17)  0.054 
Length of hospital stay (days), median 
(IQR)b 
14.0 (8.0 – 24.0) 12.0 (10.0 – 18.0) 0.98 (0.94 - 1.01) 0.137 0.96 (0.92 – 1.00)h 0.035 
Length of ICU stay (days), median (IQR)b  11.0 (6.0 – 16.0) 11.0 (5.0 – 13.0) 0.98 (0.94 - 1.02) 0.168   
Duration of mechanical ventilation (days), 
median (IQR)b 
11.0 (6.0 – 16.0) 10.0 (7.0 – 13.0) 0.98 (0.94 - 1.02) 0.188   
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APACHE II score, median (IQR)c 19.0 (11.0 – 22.0) 21.0 (19.0 – 25.0) 1.07 (1.01 - 1.13) 0.020 1.06 (0.99 – 1.14)h 0.072 
Polymicrobial infection, no. (%) 30 (50.8) 12 (48.0) 0.86 (0.39 - 1.89) 0.706   
Secondary bacteraemia, no. (%) 12 (20.3) 3 (12.0) 0.54 (0.16 - 1.81) 0.284   
Concurrent infection, no. (%) 4 (6.8) 4 (16.0) 1.58 (0.54 - 4.61) 0.426   
Infection complication, no. (%) 15 (25.4) 13 (52.0) 2.48 (1.13 - 5.45) 0.025   
Active empirical treatment, no. (%) 53 (89.8) 22 (88.0) 0.83 (0.25 – 2.78) 0.770 1.03 (0.32 – 4.57) 0.967 
Active definitive treatment, no. (%)d    0.581  0.791 
Monotherapy 38 (64.4) 17 (68.0) Ref.  Ref.  
Combination therapy 21 (35.6) 8 (32.0) 0.79 (0.34 - 1.84)  0.88 (0.35 – 2.38)  
IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; HR, hazard ratio; CI, confidence interval; Ref., reference 485 
category.  486 
a. Measured at time of admission in the ICU according to the McCabe-Jackson classification. 487 
b. Measured before the onset of infection. 488 
c. Measured at the onset of infection. 489 
d. Patients who received at least one active antibiotic. 490 
e. Excludes patients infected with a pandrug-resistant strain and those who died within 48 h of infection onset. 491 
f. Univariate Cox proportional hazards regression 492 
g. Multivariable Cox proportional hazards regression.  Likelihood ratio test = 25.205, df = 6 p<0.001. 493 
h. Hazard ratio corresponds to a unit increase in the continuous scale of the variable. 494 
 24 
Fig. 1. Kaplan-Meier survival estimates for death at 28 days after the onset of extensively 495 
drug-resistant Acinetobacter baumannii ventilator-associated pneumonia according to type of 496 
treatment: combination therapy (solid line) versus monotherapy (dashed line). P = 0.582 (log-497 
rank test). 498 
 499 
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Fig. 2. Kaplan-Meier survival estimates for death at 28 days after the onset of extensively 500 
drug-resistant Acinetobacter baumannii ventilator-associated pneumonia according to 501 
treatment regimen by log-rank test: (i) Active colistin vs active colistin + inactive 502 
carbapenem, P=0.580; (ii) Active colistin vs active colistin + inactive tigecycline, P=0.852; 503 
(iii) Active colistin vs active colistin + active tigecycline, P=0.455; (iv) Active colistin + 504 
inactive carbapenem vs active colistin + inactive tigecycline, P=0.740; (v) Active colistin + 505 
inactive carbapenem vs active colistin + active tigecycline, P=0.976; (vi) Active colistin + 506 
inactive tigecycline vs active colistin + active tigecycline, P=0.701. 507 
 508 
